CHARLES-ANDRÉ BROUWERS - CHAIRMAN OF THE BOARD

Charles-André has thirty years' experience as a consultant in the biopharmaceutical and medical device industries. He has worked closely with CEOs, senior executives and boards of directors of numerous pharmaceutical and medtech companies. Prior to founding Galileo Life Sciences, he was a Senior Partner and Managing Director of the Boston Consulting Group and previously Head of the Life Sciences Group at Capgemini.

Charles-André is a registered representative affiliated with Galileo Global Securities, LLC, an SEC-registered broker and member of the Financial Industry Regulatory Authority (FINRA).

DR. BERNARD COURTIEU

Dr. Bernard Courtieu joined IntegraGen as Chairman and CEO in September 2007. He previously held the positions of Practice Leader and Vice President at Gemini Consulting, Life Sciences Department. His successive experiences at Eurostard, Bossard Gemini Consulting and Cap Gemini Ernst & Young, have enabled him to acquire advanced expertise in operational performance development for pharmaceutical companies, in the fields of research and development, industrial operations, marketing and supply chain information systems.

Dr. Bernard Courtieu also held the position of Director France (2004) at Ariba, the world leader in "Spend Management" or helping companies to analyze and control costs. Dr. Bernard Courtieu holds an MBA from the Institut des Etudes Supérieures de l'Entreprise (IESE - Barcelona), and is a graduate of the Ecole Vétérinaire d'Alfort - Université Paris XII, France.

JEAN-POL DETIFFE

Jean-Pol Detiffe trained as an industrial pharmacist. With over twenty years' experience in healthcare, Jean-Pol is a dynamic Belgian entrepreneur who founded OncoDNA in 2012 with the ambition of helping cancer sufferers benefit from personalized tumor analysis based on the latest sequencing technologies.

Prior to founding OncoDNA, Jean-Pol was no novice, having previously founded DNAVision in 2004, the first company in Europe to offer accredited pharmacogenomic testing to the pharmaceutical industry (released in 2012).

FRANÇOIS FONTAINE

François Fontaine holds a law degree from the University of Brussels and is a specialist in tax matters. He has been an advisor to various public institutions and law firms.

He is currently General Counsel of the Société Fédérale de Participations et d'Investissement (SFPI)-FPIM. SFPI focuses its investments on innovative Belgian companies, hoping to contribute to their financial and societal success. Mr Fontaine is also a member of the board of directors of several companies, including biotechs.

FRANÇOIS BLONDEL

A graduate in Law and Economics, François Blondel combines executive positions as CEO of KitoZyme and Delphi Genetics, as well as Executive Chairman of KiOmed Pharma, with non-executive positions on boards of directors, either as Chairman of the Board or as an independent member.

Over the course of his career, François Blondel has (co)founded several start-ups and gained solid experience in managing companies active in the field of innovation. From 1999 to 2010, he was CEO of International Brachytherapy (IBt), a company listed on NYSE Euronext, which has grown from a research and development company into a diversified and successful international group, now a European leader in its market.

The companies in which he is - or has been - active range from SMEs and spin-offs, such as OncoDNA, Nanocyl and Delphi Genetics, active in the technology, medical and healthcare sectors, to large listed companies, such as RECTICEL or Compagnie du BOIS SAUVAGE, and public organizations such as AWEX, AMONIS and BioWIN.

FRANÇOIS THOMAS, M.D., PH.D.

Dr François Thomas is a venture partner at Sofimac, in charge of the Inserm Transfert Initiative (ITI) company, of which he was formerly Chairman. He is an oncologist, former clinical director at the Institut Gustave Roussy and holds an MBA from MIT (Boston).

François Thomas was successively Director of Clinical Development at Ipsen Laboratories, Managing Partner of the consulting firm Bioserve Ltd, Director of Licensing and Medical Affairs at Genset, Partner in the investment fund Atlas Venture, Head of Corporate Finance for Healthcare at Bryan Garnier and Chairman of Cythéris. Over the past 20 years, his activity has been dedicated to the creation and development of biotech companies, of which he is or has been a member of the Board of Directors of more than 20.